Replies to post #687644 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

An ASM for a hand full of retail investors with handpicked Q&A, is not the place for that conversation. LP needs to address the Institutional investment community with a plan, if she even has one that is.

[dennisdave]

NWBO will not be selling DCVAXL because they are not capable of selling, marketing, and most importantly sales supporting DCVAXL. Therefore there will be no revenue generated by NWBO as an independent biotech in the UK in 2025. Anyone who thinks a cancer drug therapy such as DCVAXL can just sells itself without any support from a well-prepared cancer drug sales support department does not understand the workings of biotech. As of today, NWBO only has Les's wife Sue Goldman to sell support the compassionate use of DCVAXL. The assertion that present NWBO/Sue will be able to explain, instruct market, and sell DCVAXL to 362 consultant neurosurgeons and or 1,078 clinical oncologists and 3,200 patients and their caregivers in the UK is absurd. As long as NWBO is not hiring a single qualified sales support staff they are not planning to sell DCVAXL. As long as NWBO is not hiring anyone to sale support DCVAXL, they are planning to be bought after UK approval.

From NWBO's last 10K

Our product candidates will require different marketing and sales methods and personnel than conventional therapeutic products. Also, we lack sales and marketing experience. These factors may result in significant difficulties in commercializing our product candidates. The commercial success of any of our product candidates will depend upon the strength of our sales and marketing efforts. We do not have a marketing or sales force and have no experience in marketing or sales of products like our lead product, DCVax-L for GBM, or our additional product, DCVax-Direct. To fully commercialize our product candidates, we will need to recruit and train marketing staff and a sales force with technical expertise and ability to manage the distribution of our DCVax-L for GBM. As an alternative, we could seek assistance from a corporate partner or a third-party services firm with a large distribution system and a large direct sales force. However, since our DCVax products are living cell, immune therapy products, and these are a fundamentally new and different type of product than are on the market today, we would still have to train such partner’s or such services firm’s personnel about our products and would have to make changes in their distribution processes and systems to handle our products. We may be unable to recruit and train effective sales and marketing forces or our own, or of a partner or a services firm, and/or doing so may be more costly and difficult than anticipated. Such factors may result in significant difficulties in commercializing our product candidates, and we may be unable to generate significant revenues.

I rest my case